CoreFirst Bank & Trust’s Takeda Pharmaceutical TAK Stock Holding History

CoreFirst Bank & Trust’s Portfolio TAK Stock Details TAK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-203	Closed	-$3.17K	–	388
2022 Q4	$3.17K	Sell	203 -503	-71%	-$7.03K	﹤0.01%	372
2022 Q3	$9K	Sell	706 -190	-21%	-$2.64K	0.01%	334
2022 Q2	$13K	Sell	896 -8,450	-90%	-$121K	0.01%	316
2022 Q1	$134K	Hold	9,346	–	–	0.09%	159
2021 Q4	$128K	Hold	9,346	–	–	0.08%	168
2021 Q3	$154K	Buy	9,346 +4,173	+81%	+$70.1K	0.11%	154
2021 Q2	$87K	Hold	5,173	–	–	0.06%	196
2021 Q1	$94K	Hold	5,173	–	–	0.06%	186
2020 Q4	$94K	Buy	+5,173	New	+$90.8K	0.07%	177

Other funds holding TAK

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Clal Insurance Tel-Aviv, Israel $22.3B AUM 79.91% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

MIP

Mondrian Investment Partners London, United Kingdom $6.48B AUM 18.36% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $23.2B AUM 40.19% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

CoreFirst Bank & Trust's TAK Position: Q1 2023 in Review

CoreFirst Bank & Trust sold out of Takeda Pharmaceutical (TAK) in Q1 2023, closing a stake of 203 shares — an estimated $3.17K sold.

CoreFirst Bank & Trust first reported a position in TAK in Q4 2020 and held it in 9 quarters. The position peaked at $154K in Q3 2021. 300 funds tracked by Wall St. Rank hold TAK as of Q1 2023.

CoreFirst Bank & Trust reported no remaining Takeda Pharmaceutical position as of Q1 2023 after selling out during the quarter.
CoreFirst Bank & Trust sold 203 Takeda Pharmaceutical shares in Q1 2023, an estimated $3.17K.
CoreFirst Bank & Trust first reported a position in Takeda Pharmaceutical in Q4 2020 and held it in 9 quarters.
CoreFirst Bank & Trust's Takeda Pharmaceutical position peaked at $154K in Q3 2021.
300 funds tracked by Wall St. Rank held Takeda Pharmaceutical as of Q1 2023.

Based on CoreFirst Bank & Trust's 13F filing for Q1 2023, filed 15 May 2023.